Evaluation of serum iron overload, AST:ALT ratio and $\log_{10}$ferritin:AST ratio among schizophrenia patients in the Kumasi Metropolis, Ghana: a case–control study

W. K. B. A. Owiredu¹, Peter Kojo Brenya¹, Yaw Osei³, Edwin Ferguson Laing¹, Clement Opoku Okrah⁴, Christian Obirikorang¹, Enoch Odame Anto¹,², Emmanuel Acheampong¹,² and Sampson Donkor¹*

Abstract

Objective: The association between unbalanced iron indices and the conditions of schizophrenia are not well understood. Liver dysfunction which has been linked to iron metabolism might be a contributing factor. This case–control study evaluated serum iron indices and liver function in treatment-naïve schizophrenia patients and those already on treatment at the Psychiatric Department of the Komfo Anokye Teaching Hospital (KATH), Kumasi-Ghana.

Results: The mean age of the respondents was $39.6 \pm 0.8$ years. Increased levels of serum iron, TS, AST, ALT and AST:ALT ratio and lower levels of UIBC, TIBC, Transferrin, and $\log_{10}$ferritin:AST ratio levels were observed among the treatment-naïve group compared to the control. The treatment-naïve and treatment groups showed significantly higher serum AST:ALT ratio, and lower $\log_{10}$ferritin:AST ratio than the healthy controls. There was a significant correlation between $\log_{10}$ferritin and AST, and $\log_{10}$ferritin and GGT in both treatments ($r = 0.343; p = 0.003$, and $r = 0.502; p = 0.001$ respectively) and treatment-naïve groups ($r = 0.348; p = 0.002$, and $r = 0.614; p < 0.001$ respectively). Percentage transferrin saturation correlated significantly with GGT only, in the treatment-naïve group ($r = 0.667; p < 0.001$), and ALT and GGT in the treatment group ($r = 0.252; p = 0.030$ and $r = 0.646; p < 0.001$ respectively).

Keywords: Iron overload, Schizophrenia, AST:ALT ratio, $\log_{10}$ferritin:AST

Introduction

According to the World Health Organization (WHO) [1], mental disorders account for five of the ten leading causes of disability and premature death worldwide, of which neuropsychiatric condition accounts for 13% of the total disability adjusted life years [1]. A prevalence based rate report from the World Mental Health Survey 2004, undertaken by WHO in Ghana estimated that, 13% of the adult population suffer from some form of mental disorder [2].

Studies in Ghana have indicated that schizophrenia is the leading psychiatric condition [3, 4]. Owiredu et al. [5] in their study in Ghana reported a prevalence of 59% for schizophrenia compared to other psychiatric conditions [5]. Serious mental illness is accompanied by higher morbidity and mortality rates of chronic diseases such as lung disease, diabetes and liver problems [6]. A previous study found that liver dysfunction is particularly elevated in adults with mental illness [7]. Iron overload has been reported to be significantly associated with liver damage [8].

Iron overload (IO) has been reported to be associated with parenchymal and organ dysfunction following abnormal of the adult population suffer from some form of mental disorder [2].
deposition of tissue iron [9, 10]. Dangers of IO in several disease conditions over the years including coronary disease [10–12], diabetes mellitus [10, 13], sexual impotence [9, 10], cerebral ischemic disease [10, 14] and neurologic or psychiatric alterations [10, 15] has been noted.

The manifestations of neuropsychiatric effects of chronic iron overload have been observed in depressives, memory loss, paranoia, visual hallucination, lethargy, disorientation, dementia, and anxiety symptoms [16, 17]. However, the pathophysiology of iron metabolism in psychiatric illnesses still remains unclear, albeit several studies have suggested a possible link between serum iron and some variables in psychiatric conditions [16, 18].

There is dearth of data on serum iron indices among psychiatric patients in Ghana, and the association between iron overload and primary psychiatric illness. Also, little is known about the liver function of psychiatric patients in Ghana. This study therefore evaluated serum iron indices and liver function among schizophrenia patients in a Ghanaian population.

Main text

Methods

Study population and setting

This case–control study was carried out at the Psychiatric department of the Komfo Anokye Teaching Hospital, Kumasi-Ghana. Qualifying patients attending the psychiatric department were recruited into the study using International classification of Diseases (ICD-10). Healthy control participants were recruited from a keep fit club. A total of 200 participants comprising 75 treatment-naïve schizophrenia patients, 75 schizophrenia patients on treatment and 50 healthy controls were recruited via purposive sampling.

Ethical consideration

The study was approved by the Committee on Human Research, Publications and Ethics (CHRPE), and the Research and Development Unit of the Komfo Anokye Teaching Hospital (KATH). Written informed consent was obtained from each participant through their legally authorised family members before enrolment into the study. All data obtained from participants was held under strict confidentiality.

Inclusion criteria

Newly diagnosed naïve schizophrenia patients and those already on any form of antipsychotic, such as olanzapine, haloperidol, risperidone etc., were included in the study. Age and sex-matched healthy individuals who were not on any medication (antibiotics, vitamins supplement), non-alcoholic, Tuberculosis free, HIV free, Hepatitis B virus free, and were not presenting any signs of chronic illness were included in the study. All respondents were ≥ 18 years.

Exclusion criteria

Schizophrenia patients already on iron therapy, non-steroidal anti-inflammatory agents, antacids, alcohol consumption, pain killers such as paracetamol etc., multiple blood transfusions and androgen/oestrogen therapy were all excluded from the study.

Questionnaire administration and sample collection

A validated questionnaire was administered to all respondents by qualified nurses to collect demographic data including age and gender. About 4 ml of venous blood sample was collected from the antecubital fossa of the study participants after an overnight fast, and sera were obtained after centrifugation. Assay parameters included: serum iron, unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC), transferrin, ferritin, percentage transferrin saturation, aspartate aminotransferase (AST), gamma glutamyl transferase (GGT) and alanine aminotransferase (ALT). AST, GGT and ALT were performed on a fully automated Mindray BS-380 auto-analyzer (Shenzhen Mindray Bio-medical electronics Co., Ltd, China). Ferritin was performed on Mindray® microplate reader MR 96 A. The assay for UIBC and iron were performed on the Mindray BA-88A Biochemistry auto-analyzer. Transferrin concentration was estimated according to Vernet [19] and Gambino et al. [20] equation.

Statistical analysis

Results are presented as mean ± SD. Analysis of variance (ANOVA) coupled with Tukey’s post hoc multiple comparisons was used to compare more than two means of continuous variables. Unpaired t-test was used to compare the means of two continuous variables. Chi-square test was used to assess the associations between categorized variables. Partial Pearson correlation was performed to test for associations between iron indices and liver function markers. A p-value < 0.05 was considered statistically significant for all analyzed data. Statistical analyses were performed using GraphPad Prism 7.

Results

Table 1 shows demographic characteristics of age and gender of the study participants. Out of the total 200 participants, 104 (52%) were females and 96 (48%) were males. The mean age of the study population was 39.6 years. There was no significant difference between the mean age of the control group compared
to the treatment (p = 0.4654) and treatment-naïve group (p = 0.4120).

Serum iron concentration and percentage transferrin saturation were significantly higher in treatment-naïve psychiatric patients compared to the control (p < 0.0001). Mean levels of transferrin, UIBC and TIBC was significantly lower in treatment-naïve psychiatric patients compared to the control (p < 0.0001). The levels of serum ferritin was highest among the treatment-naïve group, followed by the treatment group, and did not differ significantly compared to the control. Generally, the treatment-naïve group recorded the highest mean AST, ALT and GGT levels, followed by the treatment group. There was a statistically significant difference between the AST and GGT levels of the treatment-naïve group and that of the control group (p = 0.0035 and 0.0418 respectively).

Table 1 Demographic characteristics of the study participants

| Variables      | Total (n = 200) | Control (n = 50) | T (n = 75) | ³p-value | TN (n = 75) | ⁴p-value |
|----------------|-----------------|------------------|------------|----------|-------------|----------|
| Age (years)    | 39.6 ± 0.8      | 40.5 ± 1.4       | 39.0 ± 1.3 | 0.4654   | 38.9 ± 1.4 | 0.412    |
| Gender         |                 |                  |            |          |             |          |
| Male           | 96 (48.0%)      | 26 (52.0%)       | 34 (45.3%) | 0.4723   | 36 (48.0%) | 0.7169   |
| Female         | 104 (52.0%)     | 24 (48.0%)       | 41 (54.7%) |          | 39 (52.0%) |          |

Values are presented as mean ± standard deviation (SD) and frequency (proportion) where appropriate.

T = treatment, TN = treatment naïve
³p-value (comparison between control and treatment)
⁴p-value (comparison between control and treatment naïve)

Both the treatment-naïve and treatment groups had higher mean AST:ALT ratio (1.61; p = 0.0004 and 1.50; p = 0.0282 respectively) than the control group (1.29). However, mean log ferritin:AST ratio decreased significantly from the control (0.096) to treatment group (0.084, p = 0.0448) and then to the treatment-naïve group (0.080; p = 0.0113) (Table 2).

Table 2 Biochemical profile of the study participants

| Variables                  | Total (n = 200) | Control (n = 50) | T (n = 75) | ³p-value | TN (n = 75) | ⁴p-value |
|---------------------------|-----------------|------------------|------------|----------|-------------|----------|
| Markers of iron overload  |                 |                  |            |          |             |          |
| Serum iron (µmol/l)       | 37.2 ± 1.1      | 31.3 ± 1.8       | 33.5 ± 1.4 | 0.3519   | 44.9 ± 1.8 | < 0.0001 |
| Serum UIBC (µmol/l)       | 60.9 ± 1.6      | 69.6 ± 2.1       | 66.2 ± 2.5 | 0.2846   | 40.0 ± 2.5 | < 0.0001 |
| Serum TIBC (µmol/l)       | 95.2 ± 2.4      | 100.9 ± 3.7      | 99.6 ± 3.4 | 0.5374   | 84.9 ± 3.1 | < 0.0001 |
| Serum ferritin (ng/ml)    | 92.1 ± 5.1      | 81.6 ± 7.5       | 94.3 ± 8.2 | 0.2827   | 97.0 ± 10.9| 0.2956   |
| log₁₀ (ferritin)          | 1.8 ± 0.0       | 1.8 ± 0.1        | 1.9 ± 0.0  | 0.5674   | 1.9 ± 0.0  | 0.3975   |
| Serum transferrin (g/l)   | 3.8 ± 0.1       | 4.02 ± 0.1       | 3.9 ± 0.1  | 0.3761   | 3.4 ± 0.1  | < 0.0001 |
| % transferrin saturation  | 39.2 ± 0.8      | 31.01 ± 0.9      | 33.6 ± 1.0 | 0.3145   | 52.9 ± 1.6 | < 0.0001 |
| Markers of liver function |                 |                  |            |          |             |          |
| Serum AST (U/l)           | 24.7 ± 0.9      | 20.9 ± 1.2       | 23.9 ± 1.2 | 0.0773   | 28.0 ± 1.8 | 0.0035   |
| Serum ALT (U/l)           | 17.9 ± 0.6      | 17.8 ± 1.4       | 17.4 ± 0.8 | 0.8240   | 18.5 ± 1.1 | 0.6570   |
| GGT (U/l)                 | 29.3 ± 1.8      | 21.32 ± 13       | 29.7 ± 1.9 | 0.0503   | 36.98 ± 2.4| 0.0418   |
| AST:ALT ratio             | 1.5 ± 0.0       | 1.29 ± 0.0       | 1.50 ± 0.1 | 0.0282   | 1.61 ± 0.1 | 0.0004   |
| log₁₀ (ferritin):AST ratio| 0.087 ± 0.0     | 0.096 ± 0.0      | 0.084 ± 0.0| 0.0448   | 0.080 ± 0.0| 0.0113   |

Values are presented as mean ± standard deviation (SD) and frequency (proportion) where appropriate.

UIBC unsaturated iron binding capacity, TIBC total iron binding capacity, AST aspartate aminotransferase, ALT alanine aminotransferase, T treatment, GGT gamma-glutamyl transferase, TN treatment naïve
³p-value (comparison between control and treatment)
⁴p-value (comparison between control and treatment naïve)
UIBC and STIR (p < 0.0001 each), as well as higher TIBC (p = 0.0026) and log₁₀ferritin (p = 0.0035) rather than their female counterparts. There was no significant difference among gender with respect to the liver function parameters, albeit the males showed higher mean levels of AST, ALT and GGT. With the exception of the comparable means of log₁₀ferritin between the female treatment group and the female controls, all gender-matched comparisons across the various groups were statistically significant (p < 0.05).

Additional file 1: Table S1 shows the association between iron indices and liver function parameters, albeit the males showed higher mean levels of AST, ALT and GGT. With the exception of the comparable means of log₁₀ferritin between the female treatment group and the female controls, all gender-matched comparisons across the various groups were statistically significant (p < 0.05).

Discussion
In this study, the females constituted 54.7% of the treatment group. Similarly, in the treatment-naïve group, there were more females (52.0%) than males (48.0%). Owiredu et al. [5] also observed that higher prevalence of psychiatric disorders were associated with females than males in Ghana [5]. Moreover in a study by Oyane et al. [21], the female gender was more predisposed to factors of psychiatric disorders [21]. The increased female prevalence observed in the current study can be attributed to the fact that, women are emotionally and psychologically fragile in nature and are known to often internalize and brood over problems compared to men [22].

Consistent with the findings of Ikeda [23], this present study observed significantly higher serum levels of iron and percentage transferrin saturation among the treatment-naïve group compared to the treatment and control groups [23]. Moreover, the lower levels of UIBC observed among the treatment psychiatric group and the significantly lower UIBC recorded for the treatment-naïve group compared to the treatment and control groups [23]. In agreement with the fact that the liver is the main storage reserve of iron and is significantly affected by excess iron [8, 24], the treatment-naïve group in the current study presented significantly higher AST and GGT levels compared to the control group. Significantly higher AST/ALT ratio was also associated with the treatment-naïve patients compared to the controls, but the levels were comparable to the treatment group. AST/ALT ratio greater than 2:1 and increased GGT levels have been implicated in liver damage [25].

Numerous studies using experimental hepatic iron overload have identified iron-dependent oxidative damage and associated impairment of

### Tables 3 Biochemical profile of study population in relation to gender

| Parameter | Control Males (n = 26) | Control Females (n = 24) | p-value | Treatment Males (n = 34) | Treatment Females (n = 41) | p-value | Treatment-naïve Males (n = 36) | Treatment-naïve Females (n = 39) | p-value |
|-----------|-----------------------|-------------------------|---------|-------------------------|---------------------------|---------|------------------------------|---------------------------------|---------|
| Iron (µmol/l) | 26.53 ± 2.8 | 25.66 ± 1.69 | 0.092 | 26.53 ± 2.0 | 30.82 ± 2.0 | 0.057 | 25.68 ± 2.7 | 35.85 ± 2.8 | 0.0001 |
| UIBC (µmol/l) | 42.12 ± 4.40 | 39.76 ± 3.35 | 0.064 | 26.46 ± 2.06 | 25.18 ± 2.09 | 0.529 | 39.63 ± 4.02 | 33.04 ± 5.34 | 0.0001 |
| TIBC (µmol/l) | 60.65 ± 5.7 | 59.03 ± 4.03 | 0.190 | 67.14 ± 2.00 | 61.03 ± 2.00 | 0.733 | 75.96 ± 2.87 | 63.86 ± 2.61 | 0.0026 |
| log₁₀ferritin | 1.72 ± 0.05 | 1.71 ± 0.07 | 0.008 | 2.00 ± 0.04 | 1.72 ± 0.06 | 0.0005 | 1.97 ± 0.05 | 1.76 ± 0.05 | 0.0035 |
| STIR (µmol/l) | 2.29 ± 0.18 | 2.35 ± 0.13 | 0.099 | 4.12 ± 0.16 | 3.83 ± 0.21 | 0.2977 | 5.13 ± 0.23 | 4.05 ± 0.12 | 0.0001 |
| %T. saturation | 44.88 ± 1.16 | 44.52 ± 2.64 | 0.013 | 34.97 ± 1.76 | 32.02 ± 1.34 | 0.1092 | 63.56 ± 1.76 | 58.74 ± 2.64 | 0.1188 |
| AST (U/l) | 17.92 ± 1.80 | 17.17 ± 1.01 | 0.0512 | 23.03 ± 0.85 | 24.78 ± 2.00 | 0.4558 | 30.53 ± 3.21 | 25.69 ± 1.66 | 0.1756 |
| ALT (U/l) | 15.50 ± 2.07 | 14.79 ± 1.63 | 0.0668 | 18.09 ± 1.17 | 16.88 ± 1.12 | 0.4593 | 19.31 ± 1.83 | 17.82 ± 1.23 | 0.4967 |
| GGT | 21.10 ± 1.16 | 20.31 ± 1.14 | 0.0701 | 29.81 ± 1.96 | 28.12 ± 1.34 | 0.6311 | 36.81 ± 2.3 | 35.21 ± 2 | 0.5571 |

Values are presented as mean ± standard deviation (SD)

‡ p < 0.05 for comparison between male control and male T or TN group

* p < 0.05 for comparison between female control and female T or TN group

** p < 0.05 for comparison between male T and male TN group

†† p < 0.05 for comparison between male T group and the female controls, all gender-matched comparisons across the various groups were statistically significant (p < 0.05).
membrane-dependent functions of the mitochondria, microsomes, and lysosomes [26, 27]. Thus iron-induced lipid peroxidation occurs in hepatocytes and increases the risk of hepatocellular injury [28, 29]. Moreover, the current study recorded significantly lower log ferritin/AST ratio in both the treatment-naïve and treatment groups compared to the control. These significantly lower ratios among both groups may be attributed to the likelihood of liver dysfunction secondary to iron overload [8, 30].

A previous retrospective review by Feifel and Young [15] reported increased plasma iron levels of greater than 170 μg/dl; transferrin saturation greater than 50% and serum ferritin greater than 450 ng/ml among patients with bipolar disorder [15]. Iron dysregulation and overload have also been implicated in Parkinson’s disease [31], Alzheimer’s disease and dementia [32, 33]. Compared to the control group, both males and females in the treatment group reported relatively higher mean levels of iron, transferrin saturation, ALT, GGT and AST, but lower levels of UIBC in the present study. With the exception of AST, ALT and GGT levels, a similar trend observed among the treatment-naïve group revealed significant differences (p < 0.001) in relation to gender. Abnormal serum ferritin (> 300 μg/l in men and > 120 μg/l in women), and transferrin saturation (> 50%) have been reported by Cutler in a case study among psychiatric patients [34], which is consistent with the findings in the current study.

A significant positive correlation between log_{10} ferritin and AST, and log_{10} ferritin and GGT was observed in both treatment and treatment-naïve groups. This partially agrees with a previous study by Barut et al. [35] which also reported a positive correlation between ferritin and AST levels. This association has been implicated in certain disease conditions such as liver damage [36], malignancy and infection [37]. Moreover, the current study recorded a significant positive correlation between percentage transferrin saturation and GGT only, in the treatment-naïve group, and both ALT and GGT in the treatment group. The association of ferritin and transferrin saturation with the liver function markers suggests that iron metabolism may be associated with liver damage in mental illness [38].

Conclusion
Iron overload is common among schizophrenia patients in Ghana, and the iron indices are associated with AST/ALT ratio and log Ferritin:AST ratio within treatment-naïve patients. The response of these biological markers has clinical implication on liver performance; thus a possible future risk of fibrosis, mutagenesis and carcinogenesis. This emerging syndemic among schizophrenia patients in Ghana therefore necessitates baseline and periodic medical assessment of iron indices as standard components in the management plans for psychiatric patients.

Limitations
The current study could not provide information on other potential confounding factors such as Body Mass Index (BMI), menstruation and diet patterns, and hence should be considered in future investigations. With the smaller sample size obtained in this case–control study, only a temporal relationship between iron overload and liver dysfunctions can be established. A further larger longitudinal study is warranted to validate this syndemic relationship among schizophrenics.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13104-019-4847-2.

Additional file 1: Table S1. Partial Pearson correlation between Iron markers and liver function markers among study participants.

Abbreviations
UIBC: unsaturated iron binding capacity; TIBC: total iron binding capacity; AST: aspartate transaminase; ALT: alanine transaminase; GGT: gamma-glutamyl transferase.

Acknowledgements
The authors wish to thank the students and authorities of the various faculties and departments.

Authors’ contributions
WKBAO and PKB contributed to the conception of the research idea, design, drafting and revision. YO and EFL contributed to the paper writing data analysis and interpretation. YO and EFL contributed to the paper drafting and revision. COO and CO revised the manuscript and edited the text. EOA, EA and SD contributed in data analyses, interpretation and proofreading. All authors read and approved the final manuscript.

Funding
No funding was obtained for this study.

Availability of data and materials
All data generated or analyzed during this study are included in this article and its Additional file.

Ethics approval and consent to participate
All procedures performed in this study were in accordance with the Helsinki Declaration. The study was approved by the Committees on Human Research Publication and Ethics (CHRPPE) of the Kwame Nkrumah University of Science and Technology (KNUST) and the Komfo Anokye Teaching Hospital (KATH), Kumasi. Written informed consent was obtained from each participant through their legal family member after explaining the aim of the project, and the liberty to participate or not.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
Author details
1 Department of Molecular Medicine, KNUST School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana. 2 School of Medical and Health Sciences, Edith Cowan University (ECU), Joondalup, Perth-WA, Australia. 3 Department of Physician Assistance, Faculty of Health and Allied Sciences, Garden City University College (GCUC), Kenyasi, Kumasi, Ghana. 4 Department of Medical Laboratory Technology, Faculty of Allied Health Science, KNUST, Kumasi, Ghana.

Received: 28 October 2019   Accepted: 6 December 2019

Published online: 12 December 2019

References
1. World Health Organization, W. Prevention of mental disorders: effective interventions and policy options: summary report; 2004.
2. WHO. A very progressive mental health law-Ghana. Mental Health Improvements for Nations Development (MHIND). 2007. Department of Mental Health and Substance Abuse, Geneva.
3. Sikanartey T, Eaton WW. Prevalence of schizophrenia in the Labadi district of Ghana. Acta Psychiatr Scand. 1984;69(2):156–61.
4. Turkson S, Asante K. Psychiatric disorders among offender patients in the Accra Psychiatric Hospital. West Afr J Med. 1997;16(2):88–92.
5. Owiredu W, et al. Hyperlipidaemia following treatment with antipsychotic medications. J Ghana Sci Assoc. 2009. https://doi.org/10.4314/jgsa.v11i2 .50941.
6. Robson D, Gray R. Serious mental illness and physical health problems: a discussion paper. Int J Nurs Stud. 2007;44(3):457–66.
7. Sokal J, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis. 2004;192(6):421–7.
8. Pietrangelo A. Iron and the liver. Liver Int. 2016;36:116–23.
9. Dooley J, Worwood M. Guidelines on diagnosis and therapy: genetic haemochromatosis: London: British Committee for Standards in Haematology, 2000. p. 1–33.
10. Baptista-González H, et al. Evaluation of iron overload in healthy adult residents of Mexico City. Arch Med Res. 2005;36(2):142–7.
11. Klijstein-Grobusch K, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69(6):1231–6.
12. Tuomainen T-P, et al. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998;97(15):1461–6.
13. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among US adults. Diabetes Care. 1999;22(12):1978–83.
14. Armengou A, Davalos A. A review of the state of research into the role of iron in stroke. J Nutr Health Aging. 2002;6(3):207–8.
15. Feifel D, Young CW. Iron overload among a psychiatric outpatient population. J Clin Psychiatry. 1997;58(2):74–8.
16. Ayd FJ. Lexicon of psychiatry, neurology, and the neurosciences. Baltimore: Lippincott Williams & Wilkins; 2000.
17. Cutler P. Iron overload in psychiatric illness. Am J Psychiatry. 1991;148(1):147–8.
18. Essuman EE. Study of trace elements levels and oxidative stress in Ghanaian psychiatric patients receiving medication and treatment naive patients. 2012.
19. Vernet M. Immunochemical assay of transferrin and iron saturation in serum. Clin Chem. 1993;39(11):2352–3.
20. Gamblin R, et al. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum. Clin Chem. 1997;43(12):2408–12.
21. Öyane NM, et al. Seasonal variations in mood and behaviour associated with gender, annual income and education: the Hordaland Health Study. Eur J Epidemiol. 2005;20(11):929–37.
22. Gore-Felton C, et al. Relationships of sexual, physical, and emotional abuse to emotional and behavioral problems among incarcerated adolescents. J Child Sex Abuse. 2002;10(1):73–88.
23. Ikeda M. Iron overload without the C282Y mutation in patients with epilepsy. J Neurol Neurosurg Psychiatry. 2001;70(4):551–3.
24. Pelusi S, Valentì L, Fargion S. Oxidative stress and hepatic iron overload, in studies on hepatic disorders. New York: Springer; 2013. p. 345–56.
25. Berger SH, Ford RM. Alcoholic liver disease and nonalcoholic fatty liver disease. Sitaraman and Friedman’s essentials of gastroenterology. Hoboken: Wiley; 2017. p. 211–25.
26. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology. 1990;11(1):127–37.
27. Philippe MA, Ruddell RG, Ramm GA. Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol. 2007;13(35):4746.
28. Olynyk JK, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341(10):718–24.
29. Bacon BR, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328–43.
30. Unlüsoy Aksu A, et al. Iron overload in the liver of 2 children: nonalcoholic steatohepatitis and juvenile hemochromatosis. J Pediatr Hematol Oncol. 2017;39(6):466–9.
31. Chen L-L, et al. Iron dysregulation in Parkinson’s disease: focused on the autophagy-lysosome pathway. ACS Chem Neurosci. 2018;9(12):241–56.
32. Hosking DE, et al. More evidence is needed, incident cognitive decline and dementia a systematic review. Ther Adv Chronic Dis. 2018;9(12):241–56.
33. Vance E, et al. Failure to detect synergy between variants in transferrin and hemochromatosis and Alzheimer’s disease in a large cohort. bioRxiv. 2019:649962.
34. Cutler P. Iron overload and psychiatric illness. Can J Psychiatry. 1994;39(1):8–11.
35. Barut S, et al. Increased serum ferritin levels in patients with Crimean-Congo hemorrhagic fever: can it be a new severity criterion? Int J Infect Dis. 2010;14(1):e50–4.
36. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology. 1975;68(3):525–33.
37. Worwood M, Cook JD. Serum ferritin. CRC Crit Rev Clin Lab Sci. 1979;10(2):171–204.
38. Milic S, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:144.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.